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This multicentre, open-label, controlled clinical trial assessed the effects of epoetin alfa treatment on haematologic and quality of life
(QOL) parameters in 182 anaemic (Hbp12gdl
 1) ovarian cancer patients receiving platinum chemotherapy. Patients were
randomised 2:1 to receive epoetin alfa 10000–20000 IU three times weekly plus best standard treatment (BST) or BST only. Main
study end points were changes from baseline in haemoglobin (Hb) level, transfusion requirements, and QOL. For the epoetin alfa
group, mean Hb increased by 1.8gdl
 1 by weeks 4–6 and was significantly increased from baseline through study end (Po0.001).
The mean change in Hb from baseline was significantly (Po0.001) greater for epoetin alfa than BST patients at all postbaseline
evaluations. Significantly fewer epoetin alfa than BST patients required transfusion(s) after the first 4 weeks of treatment (7.9 vs 30.5%;
Po0.001). Also, significant (Pp0.04) differences favouring the epoetin alfa group over the BST group were found for all three median
CLAS scores (Energy Level, Ability to Do Daily Activities, Overall QOL) and the median average CLAS score during chemotherapy.
These findings support use of epoetin alfa to increase Hb levels, reduce transfusion use, and improve QOL in anaemic ovarian cancer
patients receiving platinum chemotherapy.
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Ovarian cancer is the fourth most common cancer in women and
the second most common gynaecological cancer (Harries and
Gore, 2002a,b). Although the 5-year survival rate for women with
low-risk stage I epithelial ovarian cancer can be as high as 90%
(Memarzadeh and Berek, 2001), this form of cancer is frequently
not detected until it is in its advanced stages with corresponding
5-year survival rates of 20–40 and 10% for stage III and stage IV
disease, respectively (Heintz et al, 2001). Standard therapy for
ovarian cancer is cytoreductive surgery, followed in most cases
by platinum/paclitaxel combination chemotherapy (Harries and
Gore, 2002a). Although chemotherapy has been shown to increase
survival for women with ovarian cancer, most eventually relapse
and die (Harries and Gore, 2002b). Therefore, palliating symptoms
and maintaining quality of life (QOL) have become primary goals
in disease management.
Anaemia in ovarian cancer patients, while often related to the
disease itself, also commonly results from myelosuppression
induced by repeated cycles of platinum-based chemotherapy. In
a large-scale audit of patients in the United Kingdom receiving
chemotherapy, which included 856 patients with ovarian cancer,
the proportion of ovarian cancer patients with anaemia (haemo-
globin (Hb) o11gdl
 1) rose from about 25% after chemotherapy
cycle 1 to 50% after cycle 6, despite 41% of these patients
having received at least one blood transfusion during treatment
(Barrett-Lee et al, 2000). The most commonly administered
chemotherapeutic agents administered in this subgroup were
carboplatin (63%), and a combination of doxorubicinþ
cisplatinþcyclophosphamide (15%).
It is well known that severe anaemia is associated with an array
of debilitating symptoms; however, even mild anaemia (Hb level
10–12gdl
 1) can have serious negative consequences for patients.
An Hb level o12gdl
 1 has been associated with increased risk
of transfusion (Ray-Coquard et al, 1999), increased fatigue (Cella,
1997; Holzner et al, 2002), and a less-than-optimal QOL (Crawford
et al, 2002). Recently, important data on anemia and performance
status were obtained by the European Cancer Anaemia Survey
(ECAS). A prospective, multinational observational survey, ECAS
evaluated the prevalence, incidence, and treatment of anaemia in
15367 European cancer patients, 1741 of whom had gynaecologic
malignancies (Ludwig et al, 2004). Analysis of the survey data
showed that the prevalence and incidence of anaemia in the
gynaecologic subgroup were 81.4 and 74.8%; however, despite its
high prevalence and incidence, anaemia remained untreated in
57.3% of patients with this symptom (Barrett-Lee et al, 2005). The
analysis additionally showed a significant correlation between
low Hb levels and poor performance score, as assessed by WHO
criteria (Po0.001, R¼ 0.18). From this it can be inferred that a
substantial proportion of anemic gynaecologic cancer patients
experience a decline in functional capacity, with a subsequent
decline in QOL. Given the many negative consequences of anaemia
for ovarian cancer patients, maintaining optimal Hb levels should
be considered an essential aspect of supportive care.
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placebo-controlled, and open-label studies to increase Hb levels in
cancer patients receiving platinum- or nonplatinum-based chemo-
therapy, correcting anaemia, decreasing transfusion requirements,
and subsequently improving patients’ QOL (Abels, 1992; Leitgeb
et al, 1994; Glaspy et al, 1997; Demetri et al, 1998; Dammacco et al,
2001; Gabrilove et al, 2001; Littlewood et al, 2001; Thomas, 2002;
Janinis et al, 2003; Shasha et al, 2003; Savonije et al, 2004; Chang
et al, 2005; Witzig et al, 2005). However, few studies to date have
examined the outcome of anaemia treatment in ovarian cancer
patients, and none have specifically evaluated the impact of
anaemia treatment on QOL in this population (ten Bokkel Huinink
et al, 1998). Given the relative lack of data on anaemia treatment
in ovarian cancer patients, we conducted a study to determine
the possible benefits of epoetin alfa treatment with respect to
transfusion reduction, QOL, and anaemia-related symptoms,
including fatigue, in anemic ovarian cancer patients.
MATERIALS AND METHODS
Study patients and design
This was a phase IV, multinational, multicentre, randomised,
open-label, comparative clinical trial conducted between March
1999 and June 2001. Female patients 18 years of age or older with
a confirmed diagnosis of ovarian cancer, at least mild anaemia
(Hbp12gdl
 1), and an ECOG performance score of 0, 1, 2, or 3
were enrolled. Patients were to be receiving or scheduled to receive
platinum-based chemotherapy and were to have a life expectancy
of at least 6 months. Patients with untreated iron, folate, or vitamin
B12 deficiency or anaemia due to factors other than cancer or its
treatment were excluded. Also excluded were those who had
received a blood transfusion within 14 days prior to study entry or
who had severe illness or surgery within 7 days of study entry. All
patients provided written informed consent before study entry.
The study was undertaken after approval of the protocol by the
Independent Ethics Committee of each centre, and was conducted
in accord with the Guidelines for Good Clinical Practice and the
Declaration of Helsinki, South Africa amendment 1996.
Enrolled patients were randomised 2:1 to receive either epoetin
alfa plus best standard treatment (BST; transfusion of red blood
cells, as needed) or BST only. Outside of the United States, epoetin
alfa is manufactured by Ortho Biologics, LLC, and distributed and
marketed as EPREX
s or ERYPO
s by Ortho Biotech, a division of
Janssen-Cilag. Epoetin alfa was administered initially at a dosage of
10000 IU three times weekly (t.i.w.) subcutaneously (or 5000 IU
t.i.w. for patients with body weight o45kg). The initial dose was
maintained throughout the first cycle of a 4-week cycle of
chemotherapy or the first two cycles of a three-week cycle. If, at
the end of the initial period, the reticulocyte count had not
increased by 440000ml
 1, or Hb had not increased by 41gdl
 1
above the baseline level, the dose of epoetin alfa was doubled
(maximum allowed dosage, 20000 IU t.i.w.). If the Hb level
exceeded 14gdl
 1 at any time, study drug was withheld until the
Hb level had declined to o12gdl
 1 and was then restarted at a
dose 25–50% lower than the previous dose. If the Hb level
increased by X2gdl
 1month
 1, the dose was reduced by 25–50%
to maintain the Hb rate of increase at o2gdl
 1month
 1. Dosage
reductions could be achieved by omitting one of the weekly doses
of epoetin alfa. No adjustment to the dosage was made if Hb level
increased in response to transfusion. The planned duration of
study treatment was a maximum of 28 weeks, which included 18–
24 weeks of chemotherapy (maximum, six cycles) plus up to 4
weeks after the last chemotherapy dose.
In both arms, red blood cell transfusion was permitted during
the study if judged necessary, but physicians were asked to refrain
from transfusing patients unless the Hb level was o9gdl
 1.
Administration of white cell growth factor was permitted, and a
daily dose of 200-mg elemental iron as oral iron supplementation
was recommended to prevent restriction of erythropoiesis.
Transferrin saturation p20% was considered indicative of
inadequate iron stores and iron deficiency.
Efficacy and safety evaluations
The primary efficacy end point was the difference between the
treatment groups in change in Hb level from baseline to study end.
Secondary efficacy end points included within-group change in Hb
level from baseline to study end and between-group differences in
proportions of patients considered complete responders, partial
responders, or nonresponders. Complete responders were defined
as patients who demonstrated an Hb increase X1gdl
 1 above
baseline without transfusion within the preceding 4 weeks. Partial
responders were defined as patients who achieved an Hb increase
of X0.5gdl
 1 but o1gdl
 1, and nonresponders, as those who
either were transfused or demonstrated an Hb increase of
o0.5gdl
 1 above baseline.
Other efficacy end points included change in proportion of
patients transfused and change in QOL scores from baseline to
study completion. Quality of life was assessed using the patient-
rated Cancer Linear Analog Scale (CLAS, also known as the Linear
Analog Scale Assessment (LASA)), which measures Energy Level,
Ability to Do Daily Activities, and Overall QOL, and the Functional
Assessment of Cancer Therapy-Anaemia (FACT-An), for which the
FACT-General (FACT-G Total) scale, FACT-An Fatigue subscale,
and Nonfatigue subscale were assessed. Both the FACT-An and the
CLAS scales are cancer specific and sensitive to Hb levels (Cella,
1997; Glaspy et al, 1997; Demetri et al, 1998; Gabrilove et al, 2001).
Haemoglobin levels, transfusion data, and QOL scores were
obtained within 7 days prior to the first dose of study medication
and at study completion or early termination. During the study,
Hb levels were measured and transfusion data collected on
completion of study weeks 4 or 6, 8 or 9, 12, and 16 or 18; QOL
was assessed after 4 or 6 weeks (CLAS only), 8 or 9 weeks (CLAS
and FACT-An), and 12 weeks (CLAS only). Additionally, tumour
response to chemotherapy and/or radiotherapy was assessed at
study end or the final visit.
Safety and tolerance of epoetin alfa were evaluated by the usual
methods, including monitoring adverse events. Adverse events
were reported by patients throughout the study either sponta-
neously or in response to general, nondirect questioning by the
investigator.
Statistical analyses
The primary analysis was based on the intent to treat (ITT)
population. For efficacy evaluations, changes between baseline and
each monthly value for Hb level were analysed using both analysis
of variance (ANOVA) and the Wilcoxon rank-sum test. The
proportion of patients transfused during the treatment period was
analysed by Fisher’s exact test, changes from baseline in QOL
scores were analysed using the Wilcoxon signed rank-sum test,
and tumour stage was compared using the Wilcoxon rank-sum
test. All P-values were unadjusted and were derived from two-
sided tests. A P-value of p0.05 was considered to indicate
statistical significance.
A total of 145 evaluable patients were required to complete the
study to have a 90% power to detect a difference (2.0gdl
 1)
between the epoetin alfa and BST groups in change in Hb from
baseline to last evaluation (primary variable), with randomisation
assignment to one of two treatment arms in a 2:1 ratio. Tests of
significance were one- or two-sided, with a set at 0.05 or 0.025. The
study was not powered for secondary efficacy variables, including
QOL.
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In total, 182 patients were enrolled in the study, 173 (114 epoetin
alfa; 59 BST) of whom were eligible for efficacy evaluation (ITT
population). The nine ineligible patients were excluded because
of data recording on differently designed case report forms (4),
misdiagnosis (3), or withdrawal of patient consent (2). The
majority (91) of evaluable patients were seen at centers in the
United Kingdom; the remaining patients were treated at centers
in Austria (27), Greece (26), Sweden (22), The Netherlands (5), and
Denmark (2). Of the 173 patients, 145 completed the study. The
other 28 were discontinued prematurely for the following reasons:
adverse event, insufficient response, noncompliance, asympto-
matic/cure, disease progression, chemotherapy discontinued, and
cancer not ovarian. Three of the 28 patients, all in the epoetin alfa
group, died during the study as a result of their malignancy. All
three patients were included in the study despite having a life
expectancy of o6 months at entry, and their deaths were not
unexpected.
Of 119 patients with available drug exposure information, 117
commenced dosing with 30000IUweek
 1, whereas two patients
commenced dosing with 20000 and 27000IUweek
 1, respectively.
(The two latter patients violated the protocol requirement for an
initial starting dose of 30000IUweek
 1, but this was considered a
minor violation and the patients were therefore included for
analysis.) In total, 10 patients (8%) required dose increases during
the study.
Baseline demographic and clinical characteristics were generally
comparable between the two treatment groups (Table 1). Mean Hb
levels at baseline were 10.8gdl
 1 for patients given epoetin alfa
and 10.7gdl
 1 for those given BST. More than 90% of the patients
in each group were receiving carboplatin or carboplatin plus
paclitaxel, and the remainder were receiving cisplatin. The
frequencies of 3- and 4-week chemotherapy cycles also were
comparable between the two groups (3-week cycles: epoetin alfa,
73.7%; BST, 72.9%) (4-week cycles: epoetin alfa, 26.3%; BST,
27.1%).
Haematopoietic response
The evaluation of haematopoietic response was based on the 171
patients who received uninterrupted treatment. In the epoetin alfa
group, the Hb level increased by a mean of 1.8gdl
 1 after the first
4–6 weeks of treatment, and was significantly (Po0.001) increased
above baseline at all time points (Figure 1). In contrast, Hb levels
in the BST group changed little over the course of treatment.
Differences between the epoetin alfa and BST groups were
significant (Po0.001, ANOVA or t-test) at all post-baseline
evaluations. The highest Hb levels in the epoetin alfa group were
observed after weeks 8–9 and 12. Mean7s.d. increases in Hb level
from baseline after 8–9 weeks were 2.071.5gdl
 1 for the epoetin
alfa group vs 0.371.0gdl
 1 for the BST group; corresponding
values after 12 weeks were 1.871.3 vs 0.071.1gdl
 1. At study
completion or early termination, mean changes in Hb level from
baseline were 1.671.5 and 0.371.3gdl
 1, respectively, for the
epoetin alfa and BST groups.
The distribution of patients in the two treatment groups by Hb
level during treatment is illustrated in Figure 2. As shown, patients
treated with epoetin alfa above the 25th percentile had Hb values
higher than those for BST patients in the 75th percentile at weeks
8–9 and week 12, and in the 95th percentile after weeks 16–18.
Median (interquartile range) Hb levels for the epoetin alfa and BST
groups were 13.0 (2.5) vs 11.0 (1.4)gdl
 1, respectively, after 8–9
weeks, and 12.9 (1.5)gdl
 1 vs 10.8 (1.5) gdl
 1, respectively, after
12 weeks. Overall, more patients in the epoetin alfa group than in
the BST group had Hb increased by X1gdl
 1 (responders, 78 vs
32% for epoetin alfa and BST, respectively; Table 2). Conversely,
fewer patients in the epoetin alfa group did not respond to
treatment. The difference in the proportions of both responders
Table 1 Demographic and clinical characteristics at baseline (intent-to-
treat population, N¼173)
Characteristic Epoetin alfa (n¼114)
Best standard
treatment (n¼59)
Mean age, year (7s.d.) 59.1 (710.6) 60.3 (711.2)
Range 35.0–87.0 30.0–79.0
Mean Hb level7s.d. (gdl
 1) 10.7570.94 10.6670.83
ECOG performance score (n, %)
a
0 56 (49.1) 27 (45.8)
1 47 (41.2) 29 (49.2)
2 11 (9.6) 3 (5.1)
3 0 (0.0) 0 (0.0)
4 0 (0.0) 0 (0.0)
Tumour stage, n (%)
I 12 (10.5) 10 (16.9)
II 13 (11.4) 3 (5.1)
III 58 (50.9) 32 (54.2)
IV 28 (24.6) 13 (22.0)
Unknown 3 (2.6) 1 (1.7)
Metastatic disease, n (%)
Unknown 1 (0.9) 0 (0.0)
None 27 (23.7) 13 (22.0)
Abdominal 66 (57.9) 32 (54.2)
Liver 12 (10.5) 6 (10.2)
Lymphatic 12 (10.5) 6 (10.2)
Lung 7 (6.1) 5 (8.5)
Other type 34 (29.8) 17 (28.8)
Previous surgery, n (%) 94 (82.5) 49 (83.1)
Type of chemotherapy, n (%)
Carboplatin 75 (65.8) 40 (67.8)
Carboplatin + paclitaxel 29 (25.4) 14 (23.7)
Cisplatin 10 (8.8) 5 (8.5)
a0¼able to carry out normal activities, 1¼restricted physical activity/ambulatory/
light work, 2¼ambulatory/capable of all self-care/unable to work, 3¼capable of only
limited self-care, 4¼completely disabled.
14.5
14.0
13.5
13.0
12.5
12.0
11.5
11.0
10.5
10.0
9.5
9.0
After 4–6
weeks
After 8–9
weeks
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weeks
After 16–18
weeks
Up to 28 
weeks Baseline
n = 114
n = 59
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n = 63
Epoetin alfa
Best standard treatment
*P <0.001
Hb = haemoglobin
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Figure 1 Mean haemoglobin levels7s.e. over time (epoetin alfa vs best
standard treatment).
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significant (Po0.001).
Transfusion use
A significantly smaller proportion of patients in the epoetin alfa
group (nine out of 114, or 7.9%) than in the BST group (18 out of
59, or 30.5%) were transfused at least once after the first 4 weeks
of treatment (Po0.001, Fisher’s exact test). Also, significant differ-
ences in transfusion rate favouring epoetin alfa were noted at all
evaluations except week 12, at which time the difference favoured
epoetin alfa, but not significantly: week 4 or 6, 5.9 vs 16.1%,
P¼0.048; week 8 or 9, 0.0 vs 14.0%, Po0.001; week 12:1.6 vs 5.3%,
not significant; weeks 16–18, 0.0 vs 19.2%, P¼0.007; and up to 28
weeks: 1.8 vs 13.8%, P¼0.004.
Quality of life
Of the 173 evaluable patients, 102 (64 epoetin alfa, 38 BST) had
paired CLAS data for baseline and after 12 weeks, and 141 (91
epoetin alfa, 50 BST) had such data for baseline and end of study.
Analysis of these data (Figure 3) showed significant differences
from baseline favouring epoetin alfa over BST for all three CLAS
change scores (Energy Level, Ability to Do Daily Activities, Overall
QOL) and the average median CLAS change score during
chemotherapy (Pp0.04; after 12 weeks: Pp0.003; Wilcoxon signed
rank-sum test). At the final visit, the median increase was 10.0mm
for each parameter in the epoetin alfa group compared with
median increases of 1.25–2.85mm for these parameters in the BST
group; differences between the groups did not achieve statistical
significance (P¼0.054–0.118). Results of within-treatment analy-
sis showed that median scores for each of the three CLAS scales
and the average median CLAS score were significantly increased
from baseline at all four evaluation points in the epoetin alfa group
(Pp0.001, Wilcoxon signed rank test), whereas no significant
change from baseline was detected at any evaluation point in the
BST group. In the epoetin alfa group, the average median CLAS
score increased by 36% from baseline (56.85mm) to last
observation (77.30mm), with increases of up to 45% (to
82.70mm) noted after 12 weeks. In contrast, the BST group
showed little change in average median score from baseline
(62.00mm) to last observation (70.00mm) or to any evaluation
point during chemotherapy (maximum, 63.30mm after 8 or 9
weeks).
The study was underpowered for FACT-An analysis. However,
univariate analysis demonstrated trends favouring epoetin alfa
over BST for the FACT-An Nonfatigue score (P¼0.087) after 8–9
weeks and for the FACT-G Total (P¼0.081), FACT-An Fatigue
(P¼0.173), and FACT-An Nonfatigue (P¼0.082) subscale scores
at study end.
Tumour response
At the end of treatment, the two study groups were similar with
respect to the proportions of patients in each group with complete
response, partial response, or no response to cancer treatment
(Table 3). However, proportionally more patients in the epoetin
alfa group than in the BST group had progressive disease, although
this difference was not significant (11 vs 2%, P¼0.425).
Examination of the patients’ medical histories showed that the
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Figure 2 Box and whisker plots summarising the distribution of
haemoglobin values for all patients in the two study groups during the
treatment period. Bottom and top edges of the boxes correspond to the
25th and 75th percentiles of the sample, respectively. The central solid lines
represent the median values, and the dotted lines represent the mean
values. The bars at the ends of the vertical lines or ‘whiskers’ mark the 5 and
95% values. Any values more extreme than these are indicated by solid
black circles.
Table 2 Haematologic response by treatment group
Haematologic response
a Epoetin alfa (n¼112)
Best standard
treatment (n¼59)
Complete responders, n (%) 87 (77.7) 19 (32.2)
Partial responders, n (%) 4 (3.6) 6 (10.2)
Nonresponders, n (%) 21 (18.8) 34 (57.6)
aComplete: Hb increase of X1.0gdl
 1 above baseline without transfusion within
previous 4 weeks; partial: Hb increase of X0.5gdl
 1 but o1.0gdl
 1; no response:
need for transfusion within previous 4 weeks or Hb increase of o0.5gdl
 1 above
baseline. The difference in the proportions of both responders and nonresponders
between the two treatment groups was statistically significant (Po0.001).
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Figure 3 Change in Cancer Linear Analog Scale (CLAS, also known as
Linear Analog. Scale Assessment (LASA)) scores from baseline after 12
weeks and at study end (epoetin alfa vs best standard treatment).
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entry.
Safety
Of the 182 patients enrolled, 181 (121 epoetin alfa, 60 BST)
received study treatment and were included in the safety analysis.
The overall incidence of adverse events was similar between the
two treatment groups; 74% of patients given epoetin alfa and 73%
of those given BST reported at least one adverse event. The most
common adverse events involved the gastrointestinal tract; these
included nausea (epoetin alfa: 18%; BST: 20%), constipation
(epoetin alfa: 15%; BST: 10%), and vomiting (epoetin alfa: 10%;
BST: 8%). A total of 12 thrombotic vascular events (TVEs) were
reported by 10 patients (8.3%) receiving epoetin alfa, including
deep vein thrombosis (three events), pulmonary embolus (three
events: two in one patient, one in another patient), cerebrovascular
accident (two events), thrombosis (two events), thrombophlebitis
(one event), and weakness on left or right side (one event); one
TVE (thrombophlebitis) was reported in one BST patient (1.7%).
Hypertension was reported in three epoetin alfa-treated patients
(mild – 1, moderate – 2). Serious adverse events (SAEs) were
reported in 23% of patients given epoetin alfa and 15% given BST.
In the epoetin alfa group, the most common SAEs were deep vein
thrombosis (three patients), and ascites, pain, vomiting, pulmo-
nary embolism, fracture, and sepsis (two patients each). In the BST
group, the most common SAEs were ascites and anemia (two
patients each). All other SAEs occurred in one patient each. Three
patients, all in the epoetin alfa group, died during the study, none
because of an adverse event related to study drug. Also, no patient
died because of a TVE, and all patients with TVEs recovered except
for one individual in the epoetin alfa group whose thrombo-
phlebitis had not yet resolved at the time of data analysis. A total of
17 patients in the epoetin alfa group but no patient in the BST
group discontinued prematurely from the study because of adverse
events.
DISCUSSION
The results of our study show that epoetin alfa can effectively
increase Hb levels and reduce transfusion use for ovarian cancer
patients receiving platinum-based chemotherapy. The mean Hb
levels for the epoetin alfa group were significantly increased from
baseline at all evaluations (Po0.001) and 78% of patients who
received epoetin alfa demonstrated a complete response to
anaemia treatment (Hb increase X1gdl
 1 without transfusion
within the previous 4 weeks). Response was rapid, with a 1.8gdl
 1
increase in mean Hb level at 4–6 weeks, and a maximum increase
of 2.0gdl
 1 at 8–9 weeks. This rate of Hb increase compares
favourably to rates seen in previous studies in patients with
gynaecologic or other tumour types. In two large studies with
patients receiving platinum or nonplatinum chemotherapy, mean
Hb increases were about 1gdl
 1 at week 4 and 2gdl
 1 at week 8
(Gabrilove et al, 2001; Littlewood et al, 2001). In a study of epoetin
alfa in patients with gynaecologic malignancies receiving poly-
chemotherapy (70% with epithelial ovarian cancer), mean Hb
increases of 1.5 and 1.6gdl
 1 were observed at 4 and 6 weeks,
respectively, with an overall mean Hb increase of 3gdl
 1 at 12
weeks (Kurz et al, 1997). The differences in rates of Hb increase
may reflect differences in baseline Hb for the populations in the
various studies; the mean baseline Hb of 10.7gdl
 1 for ovarian
cancer patients in our study was somewhat higher than that for
patients in two of the other studies (range: 9.5–9.9gdl
 1).
Although safer than in the past, blood transfusion is still
associated with numerous risks as well as substantial inconve-
nience for patients (Mohandas and Aledort, 1995), suggesting the
need for alternative anaemia therapy. For epoetin alfa-treated
patients in our study, increased Hb levels resulted in reduced
transfusion use; only 7.9% of these patients received transfusions
compared with 30.5% of BST patients (Po0.001) – a 74%
reduction in transfusion use. This result is comparable to results
from previous studies enrolling gynaecologic and ovarian cancer
patients in which epoetin treatment reduced the percentage of
patients requiring transfusion by 67–77% compared with controls
(Kurz et al, 1997; ten Bokkel Huinink et al, 1998). In studies in
patients with other malignancies, epoetin alfa treatment resulted in
reductions of approximately 36–62% in transfusion use, compared
with controls (Dammacco et al, 2001; Littlewood et al, 2001;
Pronzato et al, 2002; Janinis et al, 2003; Savonije et al, 2004; Chang
et al, 2005; Witzig et al, 2005) (Table 4).
The recognised negative impact of anaemia on cancer patient
QOL further strengthens the need for correcting this condition,
and, indeed, a number of large studies in cancer patients with a
variety of solid tumours or nonmyeloid haematologic malignancies
receiving chemotherapy have shown a positive relationship
between increases in Hb level and improvements in QOL (Abels,
1992; Leitgeb et al, 1994; Glaspy et al, 1997; Demetri et al, 1998;
Gabrilove et al, 2001; Littlewood et al, 2001; Shasha et al, 2003).
However, only limited data relating specifically to QOL in
gynaecologic cancer are available, particularly regarding the
effects of anaemia and its treatment. Analysis of a subpopulation
of gynaecologic patients from a large nonrandomised, open-label,
community-based study of epoetin alfa in patients receiving
chemotherapy showed a significant (Pp0.01) correlation between
increases in Hb level and improvement in QOL (Demetri, 1999).
Mean change in Hb exceeded 2.0gdl
 1 over the 4-month study
period, and overall transfusions were reduced from 36 to 6%
(Po0.001). Mean increases in QOL from baseline to final score
were significant (Po0.001) for Energy Level, Ability to Do Daily
Activities, and Overall Quality of Life. In a small double-blind,
placebo-controlled trial (n¼35) that enrolled anaemic (Hb
o11gdl
 1) gynaecologic patients receiving polychemotherapy,
epoetin alfa treatment increased Hb levels by 3gdl
 1 at study end
and significantly (P¼0.009) decreased transfusion use (Kurz et al,
1997). Quality of life, measured using a nonvalidated question-
naire, did not differ significantly between the groups; however,
physical activity levels improved significantly from baseline in
patients who responded to epoetin alfa.
Our study was not powered to measure absolute change in QOL,
but rather, statistical trends. Nevertheless, analysis of the QOL
data showed that patients in the epoetin alfa group achieved
significantly (Pp0.04) greater improvement than patients in the
BST group in all three median CLAS scores and in the average
median CLAS score during chemotherapy. Moreover, average
median CLAS scores for the epoetin alfa group were indicative of
significant improvement at all evaluations, whereas those for the
BST group after 12 weeks of treatment indicated a decline in QOL.
Results for the FACT analyses showed trends favouring epoetin
alfa over BST for the FACT-G and FACT-An subscale scores.
Other data indicative of a QOL benefit with epoetin alfa
treatment are provided by several randomised, controlled and
single-arm studies in cancer patients with a variety of malig-
nancies. Results of a meta-analysis involving 11459 patients from
Table 3 Tumour response to cancer treatment
Tumour response Epoetin alfa (n¼114)
Best standard
treatment (n¼59)
Complete, n (%) 55 (48) 33 (56)
Partial, n (%) 25 (22) 19 (32)
None, n (%) 7 (6) 5 (9)
Progressive disease, n (%) 13 (11) 1 (2)
Unknown, n (%) 14 (12) 1 (2)
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s23 trials showed that epoetin alfa therapy significantly improved
CLAS (20–25%), FACT-Fatigue (17%), and FACT-An (12%) scores
from baseline (P¼0.05), whereas scores for control groups were
relatively unchanged or worsened (Jones et al, 2004). Of interest,
one of these trials, a randomised, double-blind controlled study
(Littlewood et al, 2001), showed that although a significantly
greater proportion of placebo-treated patients than epoetin alfa-
treated patients were transfused, the mean Hb level of the placebo
patients was unchanged from baseline over the course of the study
and their QOL did not improve, but rather, worsened. In contrast,
epoetin alfa-treated patients demonstrated a significant increase in
Hb level from baseline, and showed significant improvement in
QOL domains.
The incidence of adverse events was similar between the epoetin
alfa and BST groups in this study, although patients in the epoetin
alfa group had a higher incidence of TVEs (12 events vs one event;
incidence 8.3 vs 1.7%). These findings are consistent with those of
other randomised studies in which patients received epoetin alfa
administered as either a t.i.w. (Dammacco et al, 2001; Littlewood
et al, 2001) or once-weekly (q.w.) (Chang et al, 2005; Witzig et al,
2005) regimen. The overall incidence of adverse events in these
studies ranged from 73 to 88% for patients in the epoetin alfa
groups and from 75 to 86% for those in the control groups. Also,
the incidence of TVEs was comparable to that reported in our
study, ranging from 5 to 10.8% for the epoetin alfa groups and 3 to
7.9% for the control groups. The Hb level required for study
enrollment/randomisation and baseline Hb in these studies are
shown in Table 4. That all erythropoiesis stimulating agents may
increase the risk for TVE development is well established and
this information is in the agents’ product labelling. It must be
mentioned in this regard, however, that the results of two recently
reported studies have suggested an adverse impact on survival
conferred by erythropoiesis stimulating agents (Henke et al, 2003;
Leyland-Jones, 2003), and that in one of the studies, increased
mortality was considered partly attributable to TVEs (Leyland-
Jones, 2003). Both studies included cancer patients who would not
normally receive erythropoiesis stimulating agents, namely,
nonanemic patients, and patients with Hb levels higher than those
recommended in the approved labelling. Interpretation of the
results of these studies is complicated due to the study designs and
imbalance of risk factors in the populations. In contrast, a meta-
analysis of 27 randomised, controlled studies (N¼3287) of
recombinant human erythropoietin (RHuEPO) showed that the
relative risk for thromboembolic complications after RHuEPO
treatment was not significantly increased compared with that of
untreated patients (RR¼1.58, 95% CI¼0.94–2.66; 12 trials,
N¼1738). The absolute risk difference was 0.02 (95% CI 0.00–
0.04), although the number of patients with no thrombotic event
may have been underreported (Bohlius et al, 2005). Further, there
was evidence of a trend toward improved overall survival with
RHuEPO treatment. From the preceding, it can be concluded that
epoetin alfa is safe and well tolerated when administered according
Table 4 Effect of epoetin alfa on transfusion: results of eight randomised, controlled studies
Authors Type study
Treatment/initial
dose Hb level criteria
Baseline Hb
level
Transfusion
requirements
after Tx
Kurz et al (1997) R, DB, C (PBO) N¼35
(gynaecologic)
EPOa 150IUkg
 1 t.i.w.
or PBO
o11gdl
 1 (for inclusion) Mean:
EPOa: 9.9gdl
 1
PBO: 9.8gdl
 1
EPOa: 21.7%
PBO: 66.6%
(P¼0.009)
Dammacco et al (2001) R, DB with OL phase, C
(PBO) N¼145 (multiple
myeloma)
EPOa 150IUkg
 1 t.i.w.
or PBO
o11gdl
 1 (for inclusion) Mean:
EPOa: 9.3gdl
 1
PBO: 9.6gdl
 1
EPOa: 28%
PBO: 47%
(P¼0.017)
Littlewood et al (2001) R, DB, C (PBO) N¼375
(mixed)
EPOa 150IUkg
 1 t.i.w.
or PBO
p10.5gdl
 1 or 410.5–
p12.0gdl
 1 after Hbk
X1.5gdl
 1 per chemo
cycle (for enrollment)
Mean:
EPOa: 9.9gdl
 1
PBO: 9.7gdl
 1
Total population:
EPOa: 24.7%
PBO: 39.5%
(P¼0.0057)
EPOa stratum:
410.5gdl
 1: 7.1%
p10.5gdl
 1: 28.2%
Pronzato et al (2002) R, OL, C (BST) N¼178
(interim analysis) (breast
cancer)
EPOa 10000 IU t.i.w.
or BST
10–12gdl
 1 (for initiation
of treatment)
Mean:
EPOa: 10.7gdl
 1
BST: 10.8gdl
 1
EPOa: 6.7%
BST: 16.9%
(P¼0.06)
Janinis et al (2003) R, OL, C (iron only)
N¼372 evaluable
(mixed)
EPOa 10000 IU t.i.w. +
iron or iron only
p11gdl
 1 (for
randomisation)
Median:
10.5gdl
 1 (both
groups)
EPOa + iron: 9%
Iron only: 23%
(P o 0.0001)
Savonije et al (2004) R, C (BSC) N¼315
(mixed)
EPOa 10000IU t.i.w.
or BSC
o12.1gdl
 1 (for
randomisation)
Median:
EPOa: 10.7gdl
 1
BSC: 10.8gdl
 1
EPOa: 37%
BST: 65%
(Po0.05)
Chang et al (2005) R, OL, C (SOC) N¼354
(breast cancer)
EPOa 40000IU q.w. or
SOC
p15gdl
 1 (for entry)
p12gdl
 1 (for
randomisation)
Mean:
EPOa: 11.2gdl
 1
SOC: 11.3gdl
 1
EPOa: 8.6%
SOC: 22.9%
(Po0.001)
Witzig et al (2005) R, DB, C (PBO) N¼344
(mixed)
EPOa 40000 IU q.w. or
PBO
o11.5gdl
 1 (males)
o10.5gdl
 1 (females) (for
enrollment)
Mean:
EPOa: 9.5gdl
 1
PBO: 9.4gdl
 1
EPOa: 25.3%
PBO: 39.6%
(P¼0.005)
BSC¼best standard care, BST¼best standard treatment, C¼controlled, DB¼double-blind, EPOa¼epoetin alfa, Hb¼hemoglobin, NA¼not available, NHP¼Nottingham
Health Profile, NS¼not statistically significant, OL¼open-label, PBO¼placebo, q.w.¼once weekly, R¼randomised; SOC¼standard of care, t.i.w.¼3 times a week,
Tx¼treatment.
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sto labelling, and that the risk of TVE development in cancer
patients receiving epoetin therapy may be substantially limited by
targeting the Hb concentration to around 12gdl
 1.
The natural history of ovarian cancer poses a unique challenge
to anaemia management. In the majority of patients, this cancer is
not diagnosed until it has reached more advanced stages. Although
patients with advanced ovarian cancer typically respond well to
first-line chemotherapy, most relapse and become candidates for
further chemotherapy (Harries and Gore, 2002b). Prolonged
disease, surgery, and repeated cycles of platinum-based or other
chemotherapy all contribute to the development of anaemia in this
population. Anaemia has been demonstrated to negatively affect
cancer patients by increasing risk of transfusion and reducing
QOL. The results of the present study support the use of epoetin
alfa in anemic ovarian cancer patients to achieve a reliable
haematologic response that is maintained throughout treatment.
Evidence from this study further supports increasing Hb levels to
ameliorate anaemia as a means of improving QOL – a primary goal
of treatment for ovarian cancer patients with advanced disease and
disease- or treatment-related anemia.
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